The vaccine has been troubled by rare instances of blood clots reported in recipients, leading some countries in Europe to restrict its use to certain older age groups or suspend it all together.
The vaccination campaign will continue without the shot from the British-Swedish company, Danish Health Administration Soren Brostrom said at a press conference in Copenhagen on Wednesday.
EU regulators also acknowledged a link between unusual clotting and the coronavirus shot in "very rare" cases, but upheld their endorsement of the drug's use in all adults.
The drugmaker also noted that, according to the latest data, the vaccine was well-tolerated, and no safety concerns related to the vaccine were identified.
THL recommends seeking treatment "immediately" for those experiencing severe, noticeably worsening headaches or very severe bruising of the skin or mucous membranes.
France, Italy, Latvia, Spain, Germany and Bulgaria announced they would restart vaccinations, while Sweden said it needs "a few days" to assess the report before lifting the ban.